HK1217698A1 - 色甘酸衍生物以及成像和治療的相關方法 - Google Patents

色甘酸衍生物以及成像和治療的相關方法

Info

Publication number
HK1217698A1
HK1217698A1 HK16105667.3A HK16105667A HK1217698A1 HK 1217698 A1 HK1217698 A1 HK 1217698A1 HK 16105667 A HK16105667 A HK 16105667A HK 1217698 A1 HK1217698 A1 HK 1217698A1
Authority
HK
Hong Kong
Prior art keywords
imaging
treatment
related methods
cromolyn derivatives
cromolyn
Prior art date
Application number
HK16105667.3A
Other languages
English (en)
Inventor
‧埃爾馬列
‧肖普
Original Assignee
Massachusetts Gen Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Gen Hospital filed Critical Massachusetts Gen Hospital
Publication of HK1217698A1 publication Critical patent/HK1217698A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/24Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/0412Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K51/0421Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK16105667.3A 2009-01-29 2016-05-17 色甘酸衍生物以及成像和治療的相關方法 HK1217698A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14824509P 2009-01-29 2009-01-29

Publications (1)

Publication Number Publication Date
HK1217698A1 true HK1217698A1 (zh) 2017-01-20

Family

ID=42396349

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16105667.3A HK1217698A1 (zh) 2009-01-29 2016-05-17 色甘酸衍生物以及成像和治療的相關方法

Country Status (9)

Country Link
US (1) US8617517B2 (zh)
EP (2) EP3567033A1 (zh)
JP (1) JP5731406B2 (zh)
CN (2) CN105061376A (zh)
AU (1) AU2010208136B2 (zh)
CA (1) CA2751125C (zh)
ES (1) ES2733214T3 (zh)
HK (1) HK1217698A1 (zh)
WO (1) WO2010088455A2 (zh)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US10058530B2 (en) 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
CN109846862A (zh) * 2012-10-25 2019-06-07 通用医疗公司 治疗阿尔茨海默病及相关疾病的组合疗法
CN103274911B (zh) * 2013-05-09 2015-04-15 浙江金伯士药业有限公司 一种1,3-二羟基-2-丙酮的制备方法
JP2016534976A (ja) * 2013-05-23 2016-11-10 アズセラピーズ インコーポレイテッド クロモリンを送達する方法
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
CN110305095A (zh) * 2013-10-22 2019-10-08 综合医院公司 色甘酸衍生物以及成像和治疗的相关方法
PT3104854T (pt) 2014-02-10 2020-06-26 Respivant Sciences Gmbh Estabilizadores de mastócitos para tratamento de doença pulmonar
WO2015120389A1 (en) 2014-02-10 2015-08-13 Patara Pharma, LLC Mast cell stabilizers treatment for systemic disorders
WO2017027402A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
WO2017027387A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of mast cell related disorders with mast cell stabilizers
CA3005887A1 (en) * 2015-11-19 2017-05-26 Aztherapies, Inc. Methods for treating alzheimer's disease and related disorders
CN108472275A (zh) 2015-11-23 2018-08-31 阿尔茨治疗方法公司 治疗缺血性中风的组合物及方法
EP3506893A4 (en) 2016-08-31 2020-01-22 Respivant Sciences GmbH CROMOLYNE COMPOSITIONS FOR THE TREATMENT OF CHRONIC COUGH DUE TO IDIOPATHIC PULMONARY FIBROSIS
US20190240194A1 (en) * 2016-08-31 2019-08-08 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
AU2017339366A1 (en) 2016-10-07 2019-04-11 Respivant Sciences Gmbh Cromolyn compositions for treatment of pulmonary fibrosis
US10561612B2 (en) 2017-07-20 2020-02-18 The General Hospital Corporation Powdered formulations of cromolyn sodium and ibuprofen
KR20210071943A (ko) 2018-07-02 2021-06-16 더 제너럴 하스피탈 코포레이션 크로몰린 소듐 및 α-락토스의 분말화된 제형
KR20210113610A (ko) * 2018-12-10 2021-09-16 더 제너럴 하스피탈 코포레이션 크로몰린 에스테르 및 이의 용도
EP4058010A1 (en) 2019-11-12 2022-09-21 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of mast cell stabilizer for the treatment of heart failure with preserved ejection fraction

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1144905A (en) * 1965-03-25 1969-03-12 Fisons Pharmaceuticals Ltd Substituted bis-(2-carboxy-chromonyl-oxy) derivatives and preparation and pharmaceutical compositions thereof
US3686412A (en) * 1965-03-25 1972-08-22 Colin Fitzmaurice Compositions containing bis-chromonyl compounds for inhibiting antigen-antibody reactions
GB1257162A (zh) * 1968-02-16 1971-12-15
US4996296A (en) 1983-07-27 1991-02-26 Yeda Research & Development Co., Ltd. Cromolyn binding protein in highly purifed form, and methods for the isolation thereof
US4919915A (en) * 1987-03-03 1990-04-24 Paul Averback Method for detecting the ability to prevent red-to-green congophilic birefringence
CA2174583A1 (en) * 1995-05-05 1996-11-06 Alexander Chucholowski Sulfuric acid esters of sugar alcohols
FR2815030A1 (fr) * 2000-10-05 2002-04-12 Lipha Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant et leur utilisation pour la preparation de medicaments
US6511960B2 (en) * 2001-01-05 2003-01-28 Alphamed Pharmaceuticals Corp Cromolyn for eye and ear infections
EP1461031B1 (en) * 2001-11-29 2016-06-29 Emisphere Technologies, Inc. Formulations for oral administration of cromolyn sodium
US8088935B2 (en) 2003-12-23 2012-01-03 Ironwood Pharmaceuticals, Inc. Compounds and methods for the treatment of asthma
AR059356A1 (es) * 2006-02-14 2008-03-26 Astrazeneca Ab Nuevos radioligandos
US8445437B2 (en) * 2006-07-27 2013-05-21 The Brigham And Women's Hospital, Inc. Treatment and prevention of cardiovascular disease using mast cell stabilizers

Also Published As

Publication number Publication date
EP2391618B1 (en) 2019-04-03
CN105061376A (zh) 2015-11-18
JP5731406B2 (ja) 2015-06-10
WO2010088455A2 (en) 2010-08-05
AU2010208136A1 (en) 2011-08-18
EP2391618A4 (en) 2012-07-18
WO2010088455A3 (en) 2011-04-07
JP2012516356A (ja) 2012-07-19
EP2391618A2 (en) 2011-12-07
EP3567033A1 (en) 2019-11-13
ES2733214T3 (es) 2019-11-28
US20120058049A1 (en) 2012-03-08
CA2751125A1 (en) 2010-08-05
CN102341391B (zh) 2015-08-19
CA2751125C (en) 2017-06-20
CN102341391A (zh) 2012-02-01
AU2010208136B2 (en) 2015-03-05
US8617517B2 (en) 2013-12-31

Similar Documents

Publication Publication Date Title
HK1217698A1 (zh) 色甘酸衍生物以及成像和治療的相關方法
HK1173654A1 (zh) 治療化合物及相關的使用方法
EP2231019A4 (en) PHOTOACOUSTIC IMAGING DEVICES AND IMAGING METHODS
HK1171168A1 (zh) 利用拉喹莫德治療克羅恩病
IL236830A0 (en) Diazahomoredene derivatives and methods of using them
GB0922332D0 (en) Method of treatment and screening method
EP2427128A4 (en) SURGICAL PAVEMENT COVER AND METHOD OF USE
IL217292A0 (en) Polypeptides and method of treatment
EP2464297A4 (en) EXTERNAL ORTHOPEDIC FIXER AND USE METHOD THEREFOR
IL214255A0 (en) Methods and compositions for diagnosis and treatment of cancer
IL236516A0 (en) Methods and preparations for the diagnosis and treatment of cancer
EP2464227A4 (en) COMPOUNDS AND METHODS OF USE
IL215856A0 (en) Compositions and methods for treatment of cardiovascular disease
IL206491A0 (en) Treatment of produce
IL213973A0 (en) Salt of tetrahydrotriazolopyridine derivative and crystal thereof
EP2491389A4 (en) DETECTION AND TREATMENT OF NEUROTRANSMISSION DISORDERS ASSOCIATED WITH THE LRP4 RECEPTOR
EP2515652A4 (en) COMPOSITIONS AND METHODS FOR TREATING VITILIGO
AP3078A (en) Method and device for treatment of human excrement
GB201120521D0 (en) Orthotic device and method of manufacture
GB0919837D0 (en) Method of treatment and screening method
GB201017857D0 (en) Methods for diagnosis and methods of treatment
GB2470988B (en) Apparatus for and methods of fishing
EP2440238A4 (en) Methods of Treatment
ZA201200077B (en) Polypeptides and method of treatment
HK1174620A1 (zh) 吲唑基取代的二氫異噁唑並吡啶及其使用方法